4 Analysts Have This To Say About Sangamo Therapeutics
Portfolio Pulse from Benzinga Insights
Four analysts have provided ratings on Sangamo Therapeutics (NASDAQ:SGMO) over the past three months, all maintaining a 'Buy' rating with a consistent price target of $5.00. Despite the bullish sentiment, Sangamo faces financial challenges, including a significant revenue decline and poor profitability metrics.
October 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sangamo Therapeutics has received consistent 'Buy' ratings from analysts, with a stable price target of $5.00. However, the company is experiencing significant financial challenges, including a 94.79% decline in revenue and negative profitability metrics.
The consistent 'Buy' ratings suggest positive analyst sentiment, but the unchanged price target and significant financial challenges, such as a massive revenue decline and poor profitability, indicate a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100